These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25165994)

  • 1. Non-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factors.
    Edwards T; Allen E; Harding-Esch EM; Hart J; Burr SE; Holland MJ; Sillah A; West SK; Mabey D; Bailey R
    PLoS Negl Trop Dis; 2014 Aug; 8(8):e3098. PubMed ID: 25165994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass treatment with azithromycin for trachoma control: participation clusters in households.
    Ssemanda EN; Munoz B; Harding-Esch EM; Edwards T; Mkocha H; Bailey RL; Sillah A; Stare D; Mabey DC; West SK;
    PLoS Negl Trop Dis; 2010 Oct; 4(10):. PubMed ID: 20957196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting antibiotics to households for trachoma control.
    Blake IM; Burton MJ; Solomon AW; West SK; Basáñez MG; Gambhir M; Bailey RL; Mabey DC; Grassly NC
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e862. PubMed ID: 21072225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
    Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
    Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
    Harding-Esch EM; Sillah A; Edwards T; Burr SE; Hart JD; Joof H; Laye M; Makalo P; Manjang A; Molina S; Sarr-Sissoho I; Quinn TC; Lietman T; Holland MJ; Mabey D; West SK; Bailey R;
    PLoS Negl Trop Dis; 2013; 7(6):e2115. PubMed ID: 23785525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds.
    Ssemanda EN; Levens J; Mkocha H; Munoz B; West SK
    PLoS Negl Trop Dis; 2012; 6(3):e1576. PubMed ID: 22448296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population coverage and factors associated with participation following a mass drug administration of azithromycin for trachoma elimination in Amhara, Ethiopia.
    Ebert CD; Astale T; Sata E; Zerihun M; Nute AW; Stewart AEP; Gessese D; Ayenew G; Ayele Z; Melak B; Chanyalew M; Gashaw B; Tadesse Z; Callahan EK; Jenness SM; Nash SD
    Trop Med Int Health; 2019 Apr; 24(4):493-501. PubMed ID: 30674087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass drug administration for trachoma: how long is not long enough?
    Jimenez V; Gelderblom HC; Mann Flueckiger R; Emerson PM; Haddad D
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003610. PubMed ID: 25799168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study.
    Burton MJ; Holland MJ; Makalo P; Aryee EA; Alexander ND; Sillah A; Faal H; West SK; Foster A; Johnson GJ; Mabey DC; Bailey RL
    Lancet; 2005 Apr 9-15; 365(9467):1321-8. PubMed ID: 15823382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
    Ervin AM; Mkocha H; Munoz B; Dreger K; Dize L; Gaydos C; Quinn TC; West SK
    Ophthalmic Epidemiol; 2016 Dec; 23(6):347-353. PubMed ID: 27820670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia.
    Astale T; Sata E; Zerihun M; Nute AW; Stewart AEP; Gessese D; Ayenew G; Melak B; Chanyalew M; Tadesse Z; Callahan EK; Nash SD
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006270. PubMed ID: 29451881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control.
    Bojang E; Jafali J; Perreten V; Hart J; Harding-Esch EM; Sillah A; Mabey DC; Holland MJ; Bailey RL; Roca A; Burr SE
    BMC Microbiol; 2017 Mar; 17(1):75. PubMed ID: 28351345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
    Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
    Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in the Gambia.
    Burr SE; Milne S; Jafali J; Bojang E; Rajasekhar M; Hart J; Harding-Esch EM; Holland MJ; Mabey DC; Sillah A; Bailey RL; Roca A
    Bull World Health Organ; 2014 Jul; 92(7):490-8. PubMed ID: 25110374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?
    West SK; Stare D; Mkocha H; Munoz B; Gaydos C; Quinn TC
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):6040-2. PubMed ID: 21680866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
    Porco TC; Gebre T; Ayele B; House J; Keenan J; Zhou Z; Hong KC; Stoller N; Ray KJ; Emerson P; Gaynor BD; Lietman TM
    JAMA; 2009 Sep; 302(9):962-8. PubMed ID: 19724043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.
    Stare D; Harding-Esch E; Munoz B; Bailey R; Mabey D; Holland M; Gaydos C; West S
    Ophthalmic Epidemiol; 2011 Feb; 18(1):20-9. PubMed ID: 21275593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.
    Lee JS; Muñoz BE; Mkocha H; Gaydos CA; Quinn TC; West SK
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2761. PubMed ID: 24722392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coverage of azithromycin mass treatment for trachoma elimination in Northwestern Ethiopia: a community based cross-sectional study.
    Tilahun Z; Fenta TG
    BMC Ophthalmol; 2018 Aug; 18(1):193. PubMed ID: 30081851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.